Enzete - Company finances
|
EUR
|
2020
From: 2020-11-24
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|
|
Financial data
|
||||||
| Sales revenue | 0 | 41,509 | 12,372 | 9,020 | 29,206 | 11,116 |
| Profit before tax | 0 | 7,421 | -19,204 | -5,610 | 725 | -9,928 |
| Net profit | 0 | 7,038 | -19,204 | -5,610 | 725 | -9,928 |
| Equity | 0 | 7,421 | 18,958 | 13,348 | 14,073 | 4,220 |
| Liabilities | - | 30,287 | 11,793 | 17,818 | 7,146 | 6,276 |
| Non-current assets | 0 | 12,207 | 9,782 | 7,356 | 2,781 | 2,039 |
| Current assets | 0 | 28,316 | 21,647 | 20,883 | 18,391 | 8,410 |
| Total assets | 0 | 40,523 | 31,429 | 28,239 | 21,172 | 10,449 |
|
Taxes paid
|
||||||
| STI taxes | - | - | - | 2,507 | 3,424 | 1,005 |
|
Financial indicators
|
||||||
| Revenue change y/y | - | - | -70.2% | -27.1% | +223.8% | -61.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | - | 17.4% | -61.1% | -19.9% | 3.4% | -95.0% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | - | 94.8% | -101.3% | -42.0% | 5.2% | -235.3% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | - | 17.0% | -155.2% | -62.2% | 2.5% | -89.3% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | - | 17.9% | -155.2% | -62.2% | 2.5% | -89.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | 4.1 | 0.6 | 1.3 | 0.5 | 1.5 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | 29,056 | 7,423 | 5,798 | 25,554 | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Enzete - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2024-06-18 | 2024-07-09 | 0.02 |
| 2024-05-16 | 2024-06-09 | 0.02 |
| 2024-04-23 | 2024-05-09 | 0.02 |
| 2024-02-19 | 2024-02-28 | 5.50 |
| 2024-01-23 | 2024-01-30 | 0.20 |
| 2023-10-17 | 2023-10-30 | 45.88 |
| 2023-05-16 | 2023-06-30 | 0.35 |
| 2022-09-16 | 2022-09-29 | 0.54 |
| 2022-08-23 | 2022-09-01 | 0.54 |
| 2022-07-25 | 2022-07-28 | 0.54 |
| 2022-07-18 | 2022-07-24 | 0.10 |
| 2022-06-20 | 2022-06-30 | 0.10 |
| 2022-06-16 | 2022-06-19 | 155.37 |
| 2022-05-20 | 2022-05-23 | 0.10 |
| 2022-05-17 | 2022-05-19 | 176.33 |
| 2022-04-19 | 2022-05-05 | 0.10 |
Enzete - VMI tax arrears
As of 2026-09-02, the amount of overdue STI tax debt of the company Enzete is: 0 €
| From | To | Overdue, € |
|---|---|---|
| 2026-08-28 | 2026-09-02 | 0.06 |
| 2026-07-01 | 2026-07-07 | 0.06 |
| 2026-05-29 | 2026-06-05 | 0.18 |
| 2026-05-28 | 2026-05-28 | 212.01 |
| 2026-04-30 | 2026-05-27 | 0.01 |
| 2026-02-28 | 2026-03-27 | 0.08 |
| 2025-08-28 | 2025-09-26 | 1.24 |
| 2025-07-30 | 2025-08-27 | 0.24 |
| 2025-07-28 | 2025-07-29 | 221.0 |
| 2025-01-31 | 2025-02-03 | 2.34 |
| 2025-01-30 | 2025-01-30 | 203.57 |
| 2024-12-03 | 2024-12-27 | 0.08 |
| 2024-11-28 | 2024-12-02 | 154.06 |
| 2024-11-04 | 2024-11-27 | 0.06 |
| 2024-09-29 | 2024-11-03 | 0.7 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Enzete, MB (code 305661186) is a small partnership focused on research and development in medical sciences. In 2025, revenue was €11.1K, down 61.9% from 2024, while net loss widened to €9.9K and the profit margin fell to -89.3%. This followed a stronger 2024, when revenue reached €29.2K and the company reported a modest net profit of €725 after a €5.6K loss in 2023. Over the 2023–2025 period, revenue remained above the 2023 level, but profitability deteriorated sharply in the latest year. The balance sheet also contracted: total assets decreased to €10.4K from €21.2K in 2024 and €28.2K in 2023, equity declined to €4.2K, and liabilities stood at €6.3K. The equity ratio was 40.4%, debt to equity was 1.49, and asset turnover was 1.06x in 2025. Returns were negative, reflecting pressure on a small capital base.